Stage FocusSeries A, Series B+
GeographyUS, Europe, China
TypeCVC
Last Activity2024
Industry Focus
Industries
BiotechMedtech
Technical BenchStrong
Investor TypeCVC
ExposureSome DeepTech Investments
Bio
AstraZeneca's venture investing has evolved from the traditional MedImmune Ventures model ($400M, 2002-2013+) to a current structure centered on the BioVentureHub (an innovation campus) and strategic partnerships.
In 2024, AstraZeneca acquired Fusion Pharmaceuticals for radiopharmaceuticals. The AZ-CICC Healthcare Investment Fund targets China medical and biotech investments. Partners include Dai...
Notable Investments
F
Fusion PharmaceuticalsSimilar Funds
Ally Bridge Group
New York, United States
DeepTech NativeBiotechMedtechSeries ASeries B+
Bristol-Myers Squibb (Strategic Investments)
New York, United States
GeneralistBiotechMedtechAISeries ASeries B+
Novartis Venture Fund
Basel, Switzerland
GeneralistBiotechMedtechSeedSeries A
Pfizer Ventures
New York, United States
GeneralistBiotechMedtechSeedSeries A
Roche Venture Fund
Basel, Switzerland
GeneralistBiotechMedtechSeedSeries A
Sanofi Ventures
Paris, France
GeneralistBiotechMedtechSeedSeries A